Effects of Immune Checkpoint Inhibitors on Cancer Patients with Pre-existing Autoimmune Disease

Fukumi Furukawa

Article ID: 1250
Vol 5, Issue 1, 2021, Article identifier:5-6

VIEWS - 128 (Abstract) 36 (PDF)

Abstract


None.

Keywords


Immune Checkpoint Inhibitors; Malignant Melanoma; Cancer; Immune-related Adverse Events; Pre-existing Autoimmune Disease

Full Text:

PDF

References


Furukawa F. The Nobel Prize in Physiology or Medicine 2018 was awarded to cancer therapy by inhibition of negative immune regulation. Trends Immunother 2018; 2. doi:10.24294/ti.v2.i3.1065

Seidel JA, Otsuka A, Kabashima K. Treating tumors with immune checkpoint inhibitors: Rationale and limitations. Trends Immunother 2017; 1(1): 2–9. doi: 10.24294/ti.v1.i1.20

Furukawa F. Immune checkpoint inhibitors and irAEs. Trends Immunother 2018; 2. doi:10.24294/ti.v2.i2.930

Van der Kooij MK, K Suijkerbuijk KPM, Aarts MJB, et al. Safety and efficacy of checkpoint inhibition in patients with melanoma and preexisting autoimmune disease: A cohort study. Annals of In ternal Medicine 2021. doi: 10.7326/M20-3419.

Xie W, Huang H, Xiao S, et al. Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies. Autoimmunity Reviews 2020; 19(12). doi: 10.1016/j.autrev.2020.102687.

Tison A, Quéré G, Misery L, et al. Safety and effi-cacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: A nationwide, multicenter cohort study. Arthritis Rheumatol 2019; 71(12): 2100–2111. doi: 10.1002/art.41068.




DOI: http://dx.doi.org/10.24294/ti.v5.i1.1250

Refbacks

  • There are currently no refbacks.


Copyright (c) 2021 Fukumi Furukawa

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License

This site is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.